Motivated by these concerns, the β-amyloid deposition (A), pathologic tau (T), and neurodegeneration (N) framework was proposed as a potentially unbiased approach for categorizing AD patients according to their biological condition rather than cognitive function (1). This evidence concerns the gene MAPT and Alzheimer disease.